Triple-negative breast cancer is usually a triple-negative type of breast cancer that requires about two weeks between chemotherapy treatments after surgery. Triple-negative breast cancer, which means that pathologic tests for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) are all negative, usually has no clear cause, and may be caused by a genetic mutation. Women on long-term hormone replacement therapy who have not had children for the rest of their lives may be at an increased risk of developing triple-negative breast cancer. For triple-negative breast cancer, breast-conserving surgery or total mastectomy is usually required. Chemotherapy is usually needed after surgery, which can effectively avoid the recurrence or metastasis of cancer cells. The specific time of chemotherapy is usually decided according to the recovery condition of the patient’s body after surgery, which is about two weeks. If pathological test is done after surgery, if it suggests that there is lymphatic metastasis phenomenon, some auxiliary chemotherapy is also needed for treatment.